AstraZeneca : Enhertu Improves PFS In Phase 3 Trial On Metastatic Breast Cancer

AstraZeneca Plc. (AZN.L,AZN) and Daiichi Sankyo Company, Limited (DSKYF.PK) said that enhertu significantly improved progression-free survival in destiny-breast03 head-to-head phase 3 trial versus trastuzumab emtansine in patients with HER2 positive metastatic breast cancer.

The Independent Data Monitoring Committee (IDMC) recommended unblinding based on primary efficacy endpoint demonstrating superiority. The results also indicate strong trend toward improved overall survival.

In phase 3 trial, enhertu also showed a strong trend toward improved overall survival (OS) compared to trastuzumab emtansine in a key secondary endpoint, although the OS data are still immature. The safety profile of enhertu was consistent with previous clinical trials with no new safety concerns identified and no grade 4 or 5 treatment-related interstitial lung disease events.

DESTINY-Breast03 is a global, head-to-head, randomized, open-label, pivotal phase 3 trial evaluating the safety and efficacy of enhertu (5.4 mg/kg) versus trastuzumab emtansine in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

DESTINY-Breast03 enrolled approximately 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT